Discovery of Biaryl amide-containing transmembrane serine protease 2 (TMPRSS2) inhibitors for the treatment of prostate Cancer.
Results indicate that XDTM13 and XDTM14 are promising lead compounds for TMPRSS2 inhibition, with XDTM13 emerging as a particularly potent candidate for further development.